01760nas a2200289   4500000000100000008004100001260002400042653001300066100001300079700001400092700001300106700001300119700001500132700001300147700001400160700001800174700002300192700001400215700001200229700001500241700001400256700001200270700001800282245005800300856007400358520103800432       2020                            d  bFapUNIFESP (SciELO)10aCovid-191 aZaidel E1 aForsyth C1 aNovick G1 aMarcus R1 aRibeiro AL1 aPinazo M1 aMorillo C1 aEcheverria LE1 aShikanai-Yasuda MA1 aBuekens P1 aPerel P1 aMeymandi S1 aRalston K1 aPinto F1 aSosa-Estani S00aCOVID-19: Implications for People with Chagas Disease  uhttps://preprints.scielo.org/index.php/scielo/preprint/view/1144/17223 aAs the global COVID-19 pandemic advances, it increasingly impacts the vulnerable populations who already bear a heavy burden of neglected tropical diseases. Chagas disease (CD), a neglected parasitic infection, is of particular concern because of its potential to cause cardiac, gastrointestinal, and other complications which could increase susceptibility to COVID-19. The over one million people worldwide with chronic Chagas cardiomyopathy require special consideration because of COVID-19’s potential impact on the heart, yet the pandemic also affects treatment provision to people with acute or chronic indeterminate CD. In this document, a follow-up to the WHF-IASC Roadmap on CD, we assess the implications of coinfection with SARS-CoV-2 and Trypanosoma cruzi, the etiological agent of CD. Based on the limited evidence available, we provide preliminary guidance for testing, treatment, and management of patients affected by both diseases, while highlighting emerging healthcare access challenges and future research needs.